Gene editing, led by CRISPR, is expanding rapidly beyond medical applications, offering new opportunities across various biotech industries. Technological breakthroughs are fueling acceleration and ...
Zacks Investment Research on MSN
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
Intellia Therapeutics NTLA has made meaningful progress with the development of its in vivo programs. The company is currently advancing two late-stage in vivo candidates — lonvo-z (or, NTLA-2002) for ...
In the realm of agricultural research, the focus on neglected crops has been comparatively minimal despite their potential to contribute significantly to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback